Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 7/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 7/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 7/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22373218 | 0.96 | CA1 (0.38) | SIGMAR1CA1GNAI3GNAO1GNAI1 | |
| SCHEMBL22373526 | 0.95 | CCR2 (0.39) | CA1CA2GNAI3GNAO1GNAI1 | |
| SCHEMBL22372735 | 0.92 | ITGB3 (0.30) | GNAI3GNAO1GNAI1ITGB3ITGA2B | |
| SCHEMBL22372994 | 0.86 | CA2 (0.47) | SIGMAR1CA1CA2GNAI3GNAO1 | |
| SCHEMBL22373392 | 0.85 | PLAT (0.31) | — | |
| SCHEMBL26477503 | 0.85 | ZDHHC7 (0.41) | SIGMAR1CA1CA2GNAI3GNAO1 | |
| SCHEMBL22373027 | 0.83 | GNAO1 (0.40) | CA1CA2GNAI3GNAO1GNAI1 | |
| SCHEMBL22373520 | 0.83 | GNAO1 (0.40) | CA1CA2GNAI3GNAO1GNAI1 | |
| SCHEMBL22373300 | 0.83 | — | — | |
| SCHEMBL22372736 | 0.81 | ALDH1A1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11644753-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-05-09 | — | — | US | disclosed |
| US-20230131303-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-04-27 | — | — | US | disclosed |
| US-20200272049-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2020-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11644753-B2 | Resist composition and patterning process | HNRNPU, NSUN2, HNRNPR | SIGMAR1 327/4885CA1 1910/4885CA2 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.